Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Trial of Herpesvirus Treatment in Idiopathic Pulmonary Fibrosis (IPF)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. age \>21 and \<80 years~2. ability to provided informed consent~3. diagnosis of probable or definite IPF according to American Thoracic Society (ATS) criteria~4. tolerance of full-dose (2403 mg/day) pirfenidone~5. Positive serology for EBV or CMV~Exclusion Criteria:~1. FVC \< 40% predicted~2. Diffusing capacity for carbon monoxide (DLCO) \< 35% predicted (Crapo)~3. Forced expiratory volume (FEV)1/FVC \<0.7~4. Significant centrilobular emphysema (\>40% by HRCT)~5. Active tobacco use (cigarette or cigar smoking)~6. Resting oxygen saturation (SpO2) on room air \<89%~7. Listed for lung transplantation defined as being assigned a lung allocation score~8. environmental exposure (occupational, environmental, drug, etc.) felt by the principal investigator (PI) to be the etiology of the interstitial disease~9. diagnosis of collagen-vascular conditions (according to the published American College of Rheumatology criteria)~10. history of unstable or deteriorating cardiac disease~11. acute coronary syndrome, coronary artery bypass, or angioplasty within 3 months of screening~12. uncontrolled arrhythmia~13. uncontrolled hypertension~14. known HIV or hepatitis C~15. known cirrhosis or chronic active hepatitis~16. active substance or alcohol abuse~17. pregnancy or lactation~18. Women of childbearing potential who are not using a medically approved means of contraception. Subjects will be considered of childbearing potential if they are not surgically sterile or have not been postmenopausal for at least 2 years \[any subject who is postmenopausal for \< 2 years will be required to have a follicle-stimulating hormone (FSH) level to assess her potential to become pregnant~19. clinically relevant lab abnormalities (obtained within 30 days before enrollment), including:~    1. creatinine \> 2 x upper limit of normal (ULN)~   2. hematology outside of specified limits: white blood cells (WBCs) \< 3,500/mm3; hematocrit \< 25% or \> 59%; platelets \< 100,000/mm3;~   3. total bilirubin \> 2 x ULN~   4. Aspartate (AST) or alanine aminotransferases (ALT)/ serum glutamic-oxaloacetic; transaminase (SGOT), or serum glutamic pyruvic transaminase (SGPT) \> 2.0 x ULN~   5. alkaline phosphatase \> 3 x ULN~   6. albumin \< 3.0 mg/dL at screening~20. known hypersensitivity to study medication~21. any condition that, in the judgment of the PI, might cause participation in this study to be detrimental to the subject or that the PI deems makes the subject a poor candidate~22. any therapy with immunosuppressants such as prednisone, azathioprine, or mycophenolate currently or anticipated to be needed during the study period (subjects on these drugs prior to the study will require a 30-day washout period before randomization)~23. participation in another IPF clinical treatment trial during the study period (if completing another IPF clinical treatment trial, then a 30-day washout period is required before randomization)~24. requirement for chronic suppressive therapy with valacyclovir for recurrent herpes virus infection~25. History of myelodysplasia, aplastic anemia, refractory anemia, or multiple myeloma.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Valganciclovir (Type: EXPERIMENTAL): Valganciclovir 450 mg, 2 pills by mouth one time per day x 12 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo, 2 pills by mouth one time per day x 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).